Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol and preclamol.

Raclopride, a new potential antipsychotic agent blocking central dopamine (D2) receptors, was found to suppress exploratory locomotor activity, treadmill locomotion and conditioned avoidance response in rats. The threshold dose for effects in these test situations was about 0.5 mg/kg intraperitoneally. A considerably higher dose, 16 mg/kg intraperitoneally, was needed to produce maximal catalepsy. Maximal effects were obtained within 1-2 hrs and the duration of the effect was 2-8 hrs, depending on the test situation. The behavioural profile of raclopride is different from the classic antipsychotic haloperidol, blocking central dopamine (DA) receptors, as well as from the partial DA agonist preclamol, which inhibits central DA neurotransmission by activating DA autoreceptors. Thus, although similar to haloperidol in other respects, comparatively high doses of raclopride are needed to produce catalepsy, indicating less propensity to produce severe extrapyramidal side effects. Raclopride and preclamol are about equipotent in suppressing exploratory locomotor activity. However, raclopride is more potent than preclamol in suppressing treadmill locomotion, conditioned avoidance behaviour and catalepsy.

[1]  G. Zetler.  Pharmacological differentiation of "nicotinic" and "muscarinic" catalepsy. , 1971, Neuropharmacology.

[2]  V. Hillegaart,et al.  Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: A comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission , 1986, Pharmacology Biochemistry and Behavior.

[3]  V. Hillegaart,et al.  Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response , 1987, Pharmacology Biochemistry and Behavior.

[4]  V. Hillegaart,et al.  Suppression of exploratory locomotor activity and increase in dopamine turnover following the local application of cis-flupenthixol into limbic projection areas of the rat striatum , 1987, Brain Research.

[5]  S. D. Glick,et al.  Interaction of drug effects with testing procedures in the measurement of catalepsy , 1976, Neuropharmacology.

[6]  A Carlsson,et al.  Antipsychotic drugs, neurotransmitters, and schizophrenia. , 1978, The American journal of psychiatry.

[7]  B. Costall,et al.  Cholinergic- and neuroleptic-induced catalepsy: modification by lesions in the caudate-putamen. , 1971, Neuropharmacology.

[8]  S O Ogren,et al.  Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. , 1985, Biochemical pharmacology.

[9]  A. Phillips,et al.  Haloperidol-induced disruption of conditioned avoidance responding: attenuation by prior training or by anticholinergic drugs. , 1975, European journal of pharmacology.

[10]  R. Baldessarini,et al.  Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. , 1980, Annual review of neuroscience.

[11]  S H Snyder,et al.  Drugs, neurotransmitters, and schizophrenia. , 1974, Science.

[12]  N. Andén.  Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti‐acetylcholine drugs , 1972, The Journal of pharmacy and pharmacology.

[13]  U. Ungerstedt,et al.  Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. , 1970, European journal of pharmacology.

[14]  J. Hyttel,et al.  Differential reversal by scopolamine of effects of neuroleptics in rats. Relevance for evaluation of therapeutic and extrapyramidal side-effect potential. , 1981, Neuropharmacology.